LV12766A - Composition of l-dopa esters - Google Patents

Composition of l-dopa esters

Info

Publication number
LV12766A
LV12766A LV010124A LV010124A LV12766A LV 12766 A LV12766 A LV 12766A LV 010124 A LV010124 A LV 010124A LV 010124 A LV010124 A LV 010124A LV 12766 A LV12766 A LV 12766A
Authority
LV
Latvia
Prior art keywords
composition
dopa
weight
content
ethyl ester
Prior art date
Application number
LV010124A
Other languages
English (en)
Other versions
LV12766B (lv
Inventor
Isaac Milman
Daphne Atlas
Alexander Veinberg
Eldad Melamed
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Publication of LV12766A publication Critical patent/LV12766A/lv
Publication of LV12766B publication Critical patent/LV12766B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LVP-01-124A 1992-12-24 2001-08-21 L-dofa esteru sastāvs LV12766B (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (2)

Publication Number Publication Date
LV12766A true LV12766A (lv) 2001-12-20
LV12766B LV12766B (lv) 2002-03-20

Family

ID=25542272

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-01-124A LV12766B (lv) 1992-12-24 2001-08-21 L-dofa esteru sastāvs

Country Status (21)

Country Link
US (2) US5354885A (lv)
EP (2) EP0867179B1 (lv)
JP (1) JPH07285860A (lv)
CN (1) CN1083262C (lv)
AT (2) ATE178793T1 (lv)
AU (1) AU684053B2 (lv)
CA (1) CA2112160A1 (lv)
CY (1) CY2214B1 (lv)
DE (2) DE69324466T2 (lv)
DK (2) DK0610595T3 (lv)
ES (2) ES2150294T3 (lv)
FI (1) FI107994B (lv)
GR (2) GR3030073T3 (lv)
HK (1) HK1012577A1 (lv)
HU (1) HU218906B (lv)
IL (1) IL108147A (lv)
LV (1) LV12766B (lv)
NO (1) NO305932B1 (lv)
NZ (1) NZ250541A (lv)
PT (1) PT867179E (lv)
ZA (1) ZA939573B (lv)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AU7669496A (en) * 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
AU707646B2 (en) * 1995-11-06 1999-07-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
WO1999047133A1 (en) 1998-03-16 1999-09-23 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
NZ512027A (en) * 1998-11-10 2004-04-30 Teva Pharma Dispersible compositions containing L-dopa ethyl ester
NZ512030A (en) * 1998-11-10 2003-10-31 Teva Pharma Process for manufacture of L-dopa ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
WO2003042136A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
DK2630954T3 (en) 2002-03-20 2017-01-23 Civitas Therapeutics Inc PULMONAL SUBMISSION OF LEVODOPA
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
CA2536175C (en) * 2003-08-29 2013-05-28 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
AU2004280240B2 (en) * 2003-10-08 2010-04-22 SpecGx LLC Methylphenidate solution and associated methods of administration and production
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
JP5248331B2 (ja) * 2006-02-17 2013-07-31 バーズ ファーマ ゲーエムベーハー ベロリナ イノヴェイティブ リサーチ アンド ディヴェロップメント サービス 重水素化カテコールアミン誘導体およびその化合物を含む薬剤
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
BR112017023674A2 (pt) 2015-05-06 2018-07-17 Synagile Corporation suspensões farmacêuticas contendo partículas de fármaco, dispositivos para sua administração, e métodos de seu uso
WO2017032874A1 (en) * 2015-08-27 2017-03-02 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
ES2965284T3 (es) 2021-02-09 2024-04-11 Biobab R&D S L Método y uso de un enantiómero de 3,4-dihidroxifenilalanina (DOPA) para potenciar el atractivo de las plantas para los insectos beneficiosos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Also Published As

Publication number Publication date
FI935847A0 (fi) 1993-12-23
EP0610595A2 (en) 1994-08-17
EP0867179A1 (en) 1998-09-30
EP0867179B1 (en) 2000-09-06
FI107994B (fi) 2001-11-15
US5354885A (en) 1994-10-11
PT867179E (pt) 2000-12-29
LV12766B (lv) 2002-03-20
ATE196081T1 (de) 2000-09-15
ATE178793T1 (de) 1999-04-15
US5525631A (en) 1996-06-11
DE69329400T2 (de) 2001-01-18
EP0610595A3 (en) 1994-09-21
CN1083262C (zh) 2002-04-24
NZ250541A (en) 1995-12-21
EP0610595B1 (en) 1999-04-14
DE69329400D1 (de) 2000-10-12
DE69324466T2 (de) 1999-11-25
GR3034867T3 (en) 2001-02-28
HK1012577A1 (en) 1999-08-06
CN1094950A (zh) 1994-11-16
DK0610595T3 (da) 1999-10-25
FI935847A (fi) 1994-06-25
AU5257793A (en) 1994-07-07
NO934768D0 (no) 1993-12-22
HU9303748D0 (en) 1994-04-28
ES2132170T3 (es) 1999-08-16
NO934768L (no) 1994-06-27
IL108147A (en) 1998-09-24
IL108147A0 (en) 1994-04-12
GR3030073T3 (en) 1999-07-30
CA2112160A1 (en) 1994-06-25
ES2150294T3 (es) 2000-11-16
NO305932B1 (no) 1999-08-23
ZA939573B (en) 1994-08-11
JPH07285860A (ja) 1995-10-31
HU218906B (hu) 2000-12-28
CY2214B1 (en) 2002-11-08
DK0867179T3 (da) 2000-11-06
HUT68498A (en) 1995-06-28
DE69324466D1 (de) 1999-05-20
AU684053B2 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
LV12766A (lv) Composition of l-dopa esters
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
NO20022264L (no) Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav
CA2031714A1 (en) R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
AU567018B2 (en) Prazosin-pirbuterol combination for bronchoduation
OA09665A (fr) Esters d'aminoacides de l'hydroquinone, leur procédé de préparation et compositions pharmaceutiques ou cosmétiques les contenant
ATE160938T1 (de) Feste orale pharmazeutische zubereitung mit gemfibrozil als aktiver inhaltsstoff und verfahren zur herstellung
DK0541726T3 (da) Vækstfaktorsammensætninger, fremstilling og anvendelse
BR0114339A (pt) Composições farmaceuticamente aceitáveis contendo epinastina e pseudoefedrina
KR920021151A (ko) 면역억제특성을 갖는 약제학적 조성물을 제조하기 위한 인지질 유도체의 용도
KR930001906A (ko) 벤즈이미다졸린-2-옥소-1-카복실산 유도체의 용도